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RESUMEN
Antecedentes: el uso de extractos de hierbas en los últimos años ha sido de gran interés para los inves-
tigadores de todo el mundo. Las propiedades de la quercetina antoxidante juegan un papel importante 
en varios campos de la salud.
Objetivo: debido a la baja permeabilidad de la piel y la escasa solubilidad en medios acuáticos, se ha 
utilizado la formulación de liposomas de quercetina para obtener el uso tópico de esta sustancia.
Métodos: En este estudio, la quercetina liposomal se preparó mediante el método de fusión y se evalu-
aron las características fisicoquímicas de la formulación, incluido el tamaño de partícula, la eficacia de 
incorporación y la liberación de fármacos in vitro.
Resultados: El tamaño de partícula de las formulaciones estuvo entre 7,68 y 58,1 nm. La eficiencia de 
incorporación de las formulaciones estuvo en el rango de 80,55 a 96,80 por ciento. La liberación de fár-
macos in vitro de formulaciones fue de aproximadamente 60 a 70 por ciento.
Conclusión: De acuerdo con los resultados obtenidos, se puede decir que el uso de esta sustancia como 
una formulación liposomal puede mejorar las propiedades fisicoquímicas del fármaco en las condiciones 
de laboratorio y proporcionarlo como un candidato adecuado para estudios in vivo y clínicos adicion-
ales.
Palabras clave: Quercetina; Liposoma; Fusión; Tópica
ABSTRACT
Background: The use of herbal extracts in recent years has been of great interest to researchers around 
the world. Quercetin antoxidant properties play an important role in various fields of health.
Objective: Due to the low skin permeability and poor solubility in aqua media, quercetin liposome for-
mulation has been used to obtain topical use of this substance.
Methods: In this study, liposomal quercetin was prepared by fusion method and the physicochemical 
characteristics of the formulation, including particle size, incorporation efficiency and in vitro drug re-
lease were evaluated.
Results: The particle size of formulations were between 7.68 to 58.1 nm. The incorporation efficiency of 
formulations were in range of 80.55 to 96.80 percent. In vitro drug release of formulations were about 60 
to 70 percent.
Conclusion: According to the results obtained, it can be said that the use of this substance as a liposomal 
formulation can improve physicochemical properties of the drug in the laboratory conditions and pro-
vide it as a suitable candidate for further in vivo and clinical studies.
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INTRODUCTION
Quercetin with a structure of (3,3 ‘, 4’, 5,7-pentahydroxy fla-
vone) is a kind of flavonoids and a sub-branch of polyphe-
nols.1 The common sources of quercetin are: onion, apples, 
tomatoes and red wine.2 It exerts multiple pharmacological 
effects, including potent anti-oxidant activity, induction 
of apoptosis, modulation of cell cycle anti-mutagenesis, 
inhibition of angiogenesis and anti-inflammatory effects. 
Recently it has been reported that topical application of 
quercetin inhibits oxidative skin damages and the inflam-
matory processes induced by solar UV radiation.3 Topical 
use of quercetin is frequently hampered by its low skin per-
meability and poor solubility in aqua media, which make 
the development of pharmaceutical formulation difficult. 
Different strategies, such as prodrug4 and micro emul-
sion5, have been used to improve quercetin topical deliv-
ery. Quercetin is one such flavonoids which delay oxidant 
injury and cell death by scavenging oxygen radicals6, pro-
tecting against lipid peroxidation7 and thereby terminating 
the chain radical reaction, chelating metal ions, to form 
inert complexes that cannot take part in the conversion of 
superoxide radicals and hydrogen peroxide into hydroxyl 
radicals.8 studies of the topical application of compounds 
with free radical scavenging improve wound healing and 
protect tissue from oxidative damage.9
Liposomes are microscopic vesicles with an aqueous core 
surrounded by outer shell composed of phospholipids in a 
bilayer. They can incorporate a variety of hydrophilic and 
hydrophobic drugs, improve the accumulation of the drug 
at administration site, and reduce side effects.10-13 Hence, li-
posomes have been widely used as safe and effective drug 
vehicles in topical applications.14-17 liposomes offer a num-
ber of advantages in dermal and transdermal drug delivery 
as they have a high solubilization capacity and a penetra-
tion enhancer effect.18 The skin is the most superficial lay-
er of the body, which consists of three layers of epidermis 
and dermal and hypoderm. The main action of the skin is 
a protective barrier against environmental contaminants. 
Collapse of skin integrity resulting from physical damage 
can result in illness and even death. Skin is very often prone 
to oxidation, wounds and burns caused by environmental 
factors, pathological conditions or external trauma. Poor 
healing of such skin damage may result in serious compli-
cation and possible development of chronic skin lesions.19, 
20 the healing of chronic wound is a complex process that 
involves more than one physiopathological factor, such 
as inflammatory response, over production of destructive 
proteases and oxygen free radicals.21 A compression scars 
called “subcutaneous wounds” is created in patients with 
absolute rest and in people who have been in the bed for a 
long time. The main cause of the ulcer of the bed is due to 
prolonged stress on the skin and subsequent lack of blood 
supply to the organ, and if developed, it can involve muscle 
and soft tissue and even bone.22 In this study, a liposomal 
formulation prepared by the fusion method and character-
ized as a candidate for topical delivery of quercetin.
MATERIAL AND METHODS
Materials
Soy phosphatidylcholine (phospholipon 85G) was obtained 
from lipoid (Germany). Quercetin, cholesterol and HEPES 
(4-(2-Hydroxyethyl)1-piperazine ethanesulfonic acid) were 
purchased from Sigma (Germany). Propyl paraben, methyl 
paraben, propylene glycol and vitamin E were obtained 
from Merck (Germany).
Preparation of liposomes
Liposomes were prepared by the fusion method in different 
concentration of quercetin. Briefly, the lipid components 
consisted of Soy phosphatidylcholine (SPC) (20%), choles-
terol (2%), propylene glycol (3%), vitamin E (0.3%), methyl 
paraben (0.1%), propyl paraben (0.02%) were melted at 
about 75 °C. HEPES buffer (10Mm, pH 5) containing pro-
pylene glycol and quercetin in final concentration of 0.002, 
0.004 or 0.008g/ml was heated separately and was added 
up to 100% to the previously heated melted lipids, and the 
mixture homogenized with a homogenizer (Ultra-Turax 
IKA T25) for 5 min at 12,000 rpm and allow it to cool down 
to room temperature.23
Characterization of the liposomes
Particle size
The particle size of the samples were measured in triplicate 
by laser light scattering (Scatterscope 1, Qudix, South Ko-
rea). Samples were diluted in HEPES buffer to a suitable 
concentration (0.2 g formulation in 1 ml HEPES buffer).
Incorporation efficiency
Incorporation efficiency of liposomes was determined di-
rectly. Certain amounts of liposomal dispersions were cen-
trifuged (VS-35SMTI, Korea) at 20,000 rpm for 25 min at 
25°C. Precipitated pellets were re-dispersed in 2 ml triton 
X-10 and the final clear solution was analyzed for quercetin 
content using a UV spectrophotometer at 369 nm.24
In vitro drug release
Drug release studies were performed using dialysis mem-
brane method. Dialysis membranes were soaked before use 
in distilled water for 20h. 1g of formulation was placed in 
a dialysis membrane and both ends were closed. The mem-
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brane was float in a beaker containing 150 ml phosphate 
buffer (pH 7.4) and ethanol (3:1 v/v) and stirred at 200 rpm 
in 37 °C. 1 ml of receiver medium was removed at 15, 30, 
45, 60, 90, 120, 180, 240, 360 and 480 min and same volume 
of fresh medium was replaced. The samples were analyzed 
for their quercetin content. The derived concentration val-
ues were corrected by using the equation:25
Mt (n) =Vr X Cn+ Vs*Σ Cm
Mt (n) is the current cumulative mass of drug transported 
across the membrane at time t, n is the number of sampling, 
Cn is the current concentration in the receiver medium 
,ΣCm is the summed total of the previously measured con-
centration, Vr is the volume of the receiver medium, and 
Vs corresponds to the volume of the sample removed for 
analyzed26, 27.
Stability
The formulations were stored at refrigerate (4 °C) for 3 
months and the particle size and incorporation efficacy of 
the formulations were measured and compared with those 
at the time of preparation28.
Statistical analysis
All experiments were repeated three times and expressed 
as the mean ± standard deviation. One way analysis of var-
iance (ANOVA) followed by multiple comparisons Tukey 
test was used to substantiate statistical differences between 
groups. Result with P < 0.05 were considered to be signif-
icant.
RESULTS
The aim of the present work was to investigate the ability 
of new nanovesicle, to load quercetin and improve its local 
bioavailability. In this study the fusion method was used to 
prepare the topical liposomal formulations. The method is 
free of organic solvent and yield homogeneous liposomes 
with high incorporation efficacies. All experiments were re-
peated three times.
Characterization of the liposomes
Particle size
The mean particle size of the liposomal formulations was 
shown in Table 1. The larger the amount of drug used in the 
formulation, the larger the particle size. ANOVA analysis 
showed statistical significant differences between F1 (0.002 
g/ml) and F2 (0.004g/ml) (P<0.05) and also F1 (0.002 g/ml) 
and F3 (0.008 g/ml) (P<0.05).
Incorporation efficiency
The incorporation efficiency of formulations was in range 
of 80.55 to 96.80% (Table1).T test analysis showed statisti-
cal significant differences between F1 (0.002 g/ml) and F2 
(0.004 g/ml) (P<0.05). F3 was discarded from the rest of the 
study because of the sedimentation of un-loaded drug af-
ter centrifuge. The lipophilic nature of quercetin may lead 
to incorporation of this drug in between the lipid bilayers. 
This can explain the high incorporation efficiency of the 
quercetin in liposomal formulations.29
Table 1. Particle size (nm) and Incorporation efficiency (%) of 
liposomal formulations (mean ± SD)
Formulation 
(Quercetin, g/ml)
Average size 
(nm)
Incorporation 
(%)
F1(0.002g/ml) 8.68±1.74 96.80±3.81
F2(0.004g/ml) 39.4±10.09 80.55±0.019
F3(0.008g/ml) 58.1±10.72 -
In vitro drug release
The release profile of quercetin from various liposomal 
formulations was shown in Fig. 1. T test analysis showed 
statistical significant differences between F1 (0.002 g/ml) 
and F2 (0.004 g/ml) from 90 min till 480 min (P < 0.05). At 
the end of the test F1 released 22.97±0.01% of quercetin and 
F2 released 35.37±0.005% of that. But by assay of quercetin 
at the end of the test, it was assumed that 58.23±0.94% of 
quercetin in F1 and 50.06±2.39 % of quercetin in F2 has been 
remained in dialysis bag. So it can be concluded that about 
15% of released quercetin has been adsorbed by the surface 
of container and/or dialysis bag.
Figure 1. Release profiles of quercetin from various liposomal 
formulations
Stability
The results of stability study for formulations are shown 
in Table 2. Over the course of 3 months, the mean parti-
cle size of F1 changed significantly (P<0.05). F1 at the time 
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of preparation showed very low particle size ( less than 10 
nm) and this matter could be the reason of increasing parti-
cle size during 3 month storage, whereas F2 remained sta-
ble in case of particle size. This matter could be resulted by 
the presence of cholesterol that has stabilizing effect against 
aggregation and fusion of the liposomes.30 Incorporation ef-
ficacy of formulations did not significantly changed during 
3 month storage that may be due to the lipophilic nature 
of quercetin that intended to be remained in lipid vesicles.
Table 2. Particle size (nm) and Incorporation efficiency (%) of 
liposomal formulations after 3 month storage (mean ± SD)
Formulation 
(Quercetin, g/ml)
Average size 
(nm)
Incorporation (%)
F1(0.002g/ml) 24.56±8.23 82.83±19.80
F2(0.004g/ml) 39.83±4.38 80.2±12.36
DISCUSSION
The chemical structure of polyphenolic quercetin is report-
ed in Fig. 2. Quercetin is a yellow-green, polyphenolic fla-
vonol containing the 3-hydroxyflavone backbone with five 
oxydrilic group in position 3’-4’ and 3-5-731. In the present 
investigation, effective phospholipid nanovesicular formu-
lation were developed to achieve maximum loading capac-
ity and drug release.
Figure 2. Chemical structure of quercetin
Particle size has a key role in other characteristics of na-
novesicles such as liposomes. The particle sizes of lipos-
omes are shown in Table 1. As shown in Table 1, the higher 
concentration of quercetin in the formulation has led to in-
crease the mean particle size. These results are similar to 
those of Casteangia et al. study, that they used combination 
of quercetin and curcumin31.
Quercetin is a hydrophobic substance and high percentage 
of its incorporation (Table 1) is related to its tendency to 
position in between the bilayer shell of liposomes rather 
than aqueous phase. In this study F3 was excluded from 
the rest of the study because of sedimentation of un-loaded 
drug after centrifuge that could be because of saturation of 
hydrophobic regions in liposomes.
The cumulative amount of quercetin released from each 
formulation was plotted as a function of time over 480 min 
as shown in Fig. 1. Our results agree with the general con-
clusion that liposomal entrapment of drugs sustains their 
release. These results agree with the results of D. Liu et al. 
study. In his study, he compared the release of quercetin 
from solution and liposomal formulation, and finally con-
cluded that liposomal entrapment of drugs sustains their 
release.32
Stability test also showed reasonable results regarding size 
and encapsulation efficacy of F1 and F2 during 3 month 
storage.
CONCLUSION
Fusion technique is used as a method for making liposo-
mal forms in this study and resulted in preparations with 
enough viscosity for topical application. The particle size 
of the entire formulation is smaller than 60 nm. Liposomes 
showed high incorporation efficiency which may due to li-
pophilic nature of quercetin. Formulation F2 exhibited the 
highest drug release at 480 min and no significant changes 
were observed regarding particle size and incorporation ef-
ficiency during 3-month storage at 4 °C. These results sug-
gested that optimum formulation could gradually release 
quercetin and decrease adverse effects and also increased 
patient compliance. Quercetin has anti-oxidant and anti-in-
flammatory properties, but as it is mentioned in another 
studies, topical administration of quercetin in conventional 
dosage forms would not be suitable regarding anti-oxidant 
and anti-inflammatory effects whereas using lipid vehicles 
is the most suitable way to deliver and increase the reten-
tion of quercetin in the skin by weaken the barrier function 
of stratum corneum and facilitate drug permeation .
The overall results obtained in this study showed that lipos-
omes are interesting carriers of quercetin and they could be 
an appropriate candidate for topical use and further stud-
ies examining the efficacy of formulations on pressure ulcer 
is in progress.
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